Co-ingestion of NUTRALYS(®) pea protein and a high-carbohydrate beverage influences the glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses: preliminary results of a randomised controlled trial

What Was Tested

The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults.

Capillary blood samples (blood glucose and plasma insulin measurements) and venous blood samples (GIP and GLP-1 concentrations) were taken before each test and at fixed intervals for 180 min.

How the Study Was Run

The design is described as randomized, single-blind and crossover.

The participants were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether GIP (Gastric Inhibitory Polypeptide) was given.

In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

The data were compared using repeated-measures ANOVA or the Friedman test.

What Was Measured

The subject headings attached to it are Beverages, Blood Glucose, Eating, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose and Insulin.

Author keywords: Glucagon-like peptide-1, Glucose-dependent insulinotropic polypeptide and Pea protein.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (European journal of nutrition), a journal based in Germany.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.